Memantine versus pelacebo as an adjunct in the treatment of children with Attention Deficit Hyperactivity Disorder: a double-blind randomized, placebo-controlled study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200427047221N1

Enrollment

200

Registered

2021-04-19

Start date

2020-06-04

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder. Attention-deficit hyperactivity disorders

Interventions

Intervention 1: Intervention group:The amount of prescription methylphenidate in the group receiving memantine is at least 10 mg and at most 50 mg, and the amount of prescription memantine in the grou

Eligibility

Sex/Gender

All

Age

6 Years to 12 Years

Inclusion criteria

Inclusion criteria: 6 -12 years old ADHD No other psychiatric disorders No mental retardation No neurological disorders Not using other medications

Exclusion criteria

Exclusion criteria: Concomitant treatment with lamotrigine, amantadine, acetylcysteine, dicyclo-serine Concomitant use of hydrochlorothiazide, triamterene, metformin, cimetidine, ranitidine, quinidine Starting a new psychological intervention thirty days before the start of the study History of non-febrile seizures without a definite etiology Simultaneous kidney or liver disease Urinary-genital disorders that increase urinary pH (infections and RTA) No further referral to the clinic

Design outcomes

Primary

Measure	Time frame
Conner tests scores. Timepoint: 1th, 2th, 4th month. Method of measurement: Conner test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Yaser Mousavi Nodoushan

Zanjan University of Medical Sciences

drsymousavi@gmail.com+98 24 3345 4594

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026